Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05431608 · ClinicalTrials.gov registry record · Phase 1
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 7
- Study locations
NCT05431608: Active Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05431608 is a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05431608, a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 7
- Study locations
Study Summary
A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
Primary Outcome
To determine maximum tolerated dose (MTD) of MCARH109 and MCARH125 T cells in patients with refractory, persistent, or progressive MM.
Conditions Studied
Interventions
- BIOLOGICAL MCARH125
- BIOLOGICAL MCARH109
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Limited protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-06-20 |
| Est. Completion | 2026-06-20 |
| Phase | Phase 1 |
What the registry record for NCT05431608 still lists
NCT05431608 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which MCARH125 is the first listed.
NCT05431608 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05431608 about?
NCT05431608 is a clinical study titled "A Study of MCARH109 and MCARH125 in People With Multiple Myeloma". A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.
What is the current status of trial NCT05431608?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-06-20. Estimated completion is 2026-06-20.
What conditions does trial NCT05431608 study?
This clinical trial studies the following conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma.
What interventions are being tested in trial NCT05431608?
The interventions under investigation include: MCARH125 (BIOLOGICAL), MCARH109 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05431608?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05431608 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05431608's enrollment target sits among peer trials
15 408th of 438 higher than 29 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI